Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arlene Chan

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
Breast Cancer Research and Treatment|January 12, 2008
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analysesDavid Cameron, Michelle Casey, Michael Press, et al.
Breast (Edinburgh, Scotland)|January 26, 2023
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancerArlene Chan, Manuel Ruiz-Borrego, Gavin Marx, et al.
BMC Public Health|January 10, 2025
A prospective multi-site study to evaluate the performance and usability of an oral fluid-based HIV self-test in CanadaRichard A Galli, Darshanand Maraj, Kristin McBain, et al.
The Lancet. Oncology|August 13, 2013
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trialDavid Cameron, Julia Brown, Rebecca Dent, et al.
Breast Cancer Research : BCR|March 15, 2019
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trialStephen K L Chia, Miguel Martin, Frankie A Holmes, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2023
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trialFrankie A Holmes, Beverly Moy, Suzette Delaloge, et al.
The Lancet. Oncology|February 15, 2016
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialArlene Chan, Suzette Delaloge, Frankie A Holmes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2021
A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast CancerSherko Kuemmel, Mario Campone, Delphine Loirat, et al.
Clinical Breast Cancer|November 13, 2020
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET TrialArlene Chan, Beverly Moy, Janine Mansi, et al.
Cancer Discovery|December 16, 2017
Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast CancerKarina J Matissek, Maristela L Onozato, Sheng Sun, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
Breast Cancer Research and Treatment|January 12, 2008
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analysesDavid Cameron, Michelle Casey, Michael Press, et al.
Breast (Edinburgh, Scotland)|January 26, 2023
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancerArlene Chan, Manuel Ruiz-Borrego, Gavin Marx, et al.
BMC Public Health|January 10, 2025
A prospective multi-site study to evaluate the performance and usability of an oral fluid-based HIV self-test in CanadaRichard A Galli, Darshanand Maraj, Kristin McBain, et al.
The Lancet. Oncology|August 13, 2013
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trialDavid Cameron, Julia Brown, Rebecca Dent, et al.
Breast Cancer Research : BCR|March 15, 2019
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trialStephen K L Chia, Miguel Martin, Frankie A Holmes, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2023
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trialFrankie A Holmes, Beverly Moy, Suzette Delaloge, et al.
The Lancet. Oncology|February 15, 2016
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialArlene Chan, Suzette Delaloge, Frankie A Holmes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2021
A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast CancerSherko Kuemmel, Mario Campone, Delphine Loirat, et al.
Clinical Breast Cancer|November 13, 2020
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET TrialArlene Chan, Beverly Moy, Janine Mansi, et al.
Cancer Discovery|December 16, 2017
Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast CancerKarina J Matissek, Maristela L Onozato, Sheng Sun, et al.
Pageof 9